Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
High-intensity anticoagulation is essential in critical care and advanced clinical settings where rapid and effective clot control is required. Unfractionated heparin (UFH) is widely used in such scenarios due to its immediate anticoagulant effect and precise dose adjustment capabilities under continuous monitoring.
BARIHEP® (Heparin Sodium Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 25000 IU strength is positioned for intensive therapeutic anticoagulation, supporting healthcare professionals in managing high-risk thrombotic conditions across critical care and hospital environments — To Share • To Care • To Inspire.
| Specifications Table | |
| Parameter | Details |
| Brand Name | BARIHEP® |
| Generic Name | Heparin Sodium |
| Arabic Name | باريهيب هيبارين صوديوم |
| Category | Anticoagulants |
| Therapeutic Area | Unfractionated Heparin |
| Dosage Form | Injection |
| Strength | 25000 IU |
| Volume | 5 ml |
| Route / Type | Injectable |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Therapeutic anticoagulation |
| Management of high-risk thrombotic conditions |
| Intensive care anticoagulant support |
| Cardiovascular and emergency care |
| Advanced hospital treatment protocols |
| It is used for high-intensity therapeutic anticoagulation in critical and high-risk patients. |
It provides a stronger anticoagulant effect suitable for intensive care and advanced clinical scenarios.
| ICU, cardiovascular units, and emergency departments. |
| Yes, continuous medical monitoring is required for safe use. |
| 5000 IU, 10000 IU, 25000 IU |
